Interventions for preventing bone disease in kidney transplant recipients

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Palmer, Suetonia C ^a   McGregor, David O ^b   Strippoli, Giovanni F M ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Bone density drug effects ; Bone diseases etiology; prevention control ; Calcitonin therapeutic use ; Calcium therapeutic use ; Diphosphonates therapeutic use ; Female; Fractures, bone etiology; *prevention control ; Humans; Kidney diseases complications ; Kidney transplantation *adverse effects ; Male; Randomized controlled trials as topic; Vitamin D therapeutic use

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; HEPARIN CALCIUM; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

BLEEDING; CAPILLARY RESISTANCE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DESCENDING AORTA SURGERY; DEVICE; DRUG EFFICACY; HUMAN; IMMOBILIZATION; LUNG EMBOLISM; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; REVIEW; SIDE EFFECT; SKIN BRUISING; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 77950190295     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Coco 2003 {published data only} Coco M, Glicklich D, Bognar I, Burris L, Durkin P, Tellis V, et al.Randomized trial of IV pamidronate to ameliorate bone loss in renal transplant (rt) recipients [abstract]. Journal of the Amercian Society of Nephrology 2001;12(Program & Abstracts):927A. [CENTRAL: CN-00550697]
2. Coco M, Glicklich D, Burris L, Bognar I, Tellis V, Greenstein S, et al.Prospective randomised trial of IV pamidronate in renal transplant recipients: 6 and 12 month follow-up [abstract]. Journal of the American Society of Nephrology 2002;13(Program & Abstracts):10A. [CENTRAL: CN-00444866]
3. Coco M, Glicklich D, Burris L, Durkin P, Tellis V, Greenstein S, et al.Effect of IV pamidronate on bone biochemical parameters in renal transplant recipients [abstract]. Journal of the Amercian Society of Nephrology 2000;11(Sept):561A. [CENTRAL: CN-00550699]
4. * Coco M, Glicklich D, Faugere MC, Burris L, Bognar I, Durkin P, et al.Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. Journal of the American Society of Nephrology 2003;14(10):2669-76. [MEDLINE: 14514747]
5. Lee S, Glicklich D, Coco M. Pamidronate used to attenuate postrenal transplant bone loss is not associated with renal dysfunction. Nephrology Dialysis Transplantation 2004;19(11):2870-3. [MEDLINE: 15466880]
6. Cueto-Manzano 2000 {published data only} * Cueto-Manzano AM, Konel S, Freemont AJ, Adams JE, Mawer B, Gokal R, et al.Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. American Journal of Kidney Diseases 2000;35(2):227-36. [MEDLINE: 10676721]
7. De Sevaux 2002 {published data only} De Sevaux R, Hoitsma A, Corstens F, Wetzels J. Prophylaxis of bone loss after renal transplantation with calcium and vitamin D [abstract]. Journal of the Amercian Society of Nephrology 2001;12 (Program & Abstracts):929A. [CENTRAL: CN-00550384]
8. * De Sevaux RG, Hoitsma AJ, Corstens FHM, Wetzels JF. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. Journal of the American Society of Nephrology 2002;13(6):1608-14. [MEDLINE: 12039990]
9. Eid 1996 {published data only} * Eid P, Scuderi G, Aroldi A, Ciammella M, Nencioni T. Bone loss after renal transplantation: HRT versus calcitriol in postmenopausal recipients [abstract]. Osteoporosis International. 1996; Vol. 6, issue Suppl 1:294. [CENTRAL: CN-00260191]
10. El-Agroudy 2003a {published data only} * El-Agroudy AE, El-Husseini AA, El-Sayed M, Ghoneim MA. Preventing bone loss in renal transplant recipients with vitamin D. Journal of the American Society of Nephrology 2003;14(11):2975-9. [MEDLINE: 14569109]
11. El-Agroudy 2003b {published data only} El-Agroudy A, El-Husseini A, El-Sayed M, Ghoneim MA. Prevention of osteoporosis after kidney transplantation: a prospective randomized study [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):249.
12. * El-Agroudy AE, El-Husseini AA, El-Sayed M, Ghoneim MA. Preventing bone loss in renal transplant recipients with vitamin D. Journal of the American Society of Nephrology 2003;14(11):2975-9. [MEDLINE: 14569109]
13. El-Husseini 2004 {published data only} El-Husseini A, El-Agroudy A, El-Sayed M, Sobh M, Ghoneim M. Treatment of bone loss in renal transplant children and adolescents [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):544. [CENTRAL: CN-00445216]
14. El-Husseini A, El-Agroudy A, El-Sayed M, Sobh M, Ghoneim M. Treatment of bone loss with vitamin D in live related kidney transplant children and adolescents: a prospective randomized study [abstract]. 41st Congress European Renal Association European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon (Portugal). 2004:93. [CENTRAL: CN-00509176]
15. El-Husseini AA, El-Agroudy AE, El-Sayed M, Sobh MA, Ghoneim MA. A prospective randomized study for the treatment of bone loss with vitamin D during kidney transplantation in children and adolescents. American Journal of Transplantation 2004;4(12):2052-7. [MEDLINE: 15575909]
16. * El-Husseini AA, El-Agroudy AE, El-Sayed MF, Sobh MA, Ghoneim MA. Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. Pediatric Transplantation 2004; 8(4):357-61. [MEDLINE: 15265162]
17. Fan 2000 {published data only} Fan S, Almond MK, Ball E, Evans K, Cunningham J. Randomized prospective study demonstrating prevention of bone loss by pamidronate during the first year after renal transplantation [abstract]. Journal of the American Society of Nephrology 1996;7 (Program & Abstracts):1789. [CENTRAL: CN-00445275]
18. * Fan SL-S, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney International 2000;57(2):684-90. [MEDLINE: 10652047]
19. Fan SL-S, Kumar S, Cunningham J. Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney International 2003;63(6):2275-9. [MEDLINE: 12753318]
20. Giannini 2001 {published data only} Giannini S, D'Angel A, Carraro G, Nobile M, Rigotti P, Bonfante L, et al.Alendronate prevents further bone loss in renal transplant recipients. Journal of Bone & Mineral Research 2001;16(11):2111-7. [MEDLINE: 11697808]
21. Grotz 1998 {published data only} * Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A, Gunter K, et al.Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 1998;66(8):1004-8. [MEDLINE: 9808483]
22. Grotz 2001 {published data only} * Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen K-G, Uhl M, et al.Effect of ibandronate on bone loss and renal function after kidney transplantation. Journal of the American Society of Nephrology 2001;12(7):1530-7. [MEDLINE: 11423583]
23. Haas 2003 {published data only} * Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, et al.Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney International 2003;63 (3):1130-6. [MEDLINE: 12631097]
24. Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney International 2004;65(1):304-9. [MEDLINE: 14675064]
25. Schwarz C, Mittetbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney International 2004;65(1):304-9. [MEDLINE: 14675064]
26. Jeffery 2003 {published data only} Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. A randomized prospective trial of calcitriol versus alendronate for the treatment of osteopenia in renal transplant recipients [abstract]. American Journal of Transplantation 2003;3(Suppl 5):353. [CENTRAL: CN-00445907]
27. Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation 2003;76(10):1498-502. [MEDLINE: 14657693]
28. Koc 2002 {published data only} * Koc M, Tuglular H, Arikan H, Ozener C, Akoglu E. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplantation Proceedings 2002;34(6):2111-3. [MEDLINE: 12270333]
29. Koc M, Tuglular S, Arikan H, Ozener C, Akoglu E. Alendronate increases bone mineral density in renal transplant recipients [abstract]. Nephrology Dialysis Transplantation 2001;16(6):A227. [CENTRAL: CN-00446130]
30. Nam 2000 {published data only} * Nam JH, Moon JI, Chung SS, Kim SI, Park KI, Song YD, et al.Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation. Transplantation Proceedings 2000;32 (7):1876. [MEDLINE: 11119979]
31. Neubauer 1984 {published data only} * Neubauer E, Neubauer N, Ritz E, Dreikorn K, Krause KH. Bone mineral content after renal transplantation. Placebo-controlled prospective study with 1,25-dihydroxy vitamin D3. Klinische Wochenschrift 1984;62(2):93-6. [MEDLINE: 6368958]
32. Nordal 1995 {published data only} Nordal KP, Halse J, Dahl E. The effect of nasal calcitonin on bone mineral density in renal transplant recipients [abstract]. Nephrology Dialysis Transplantation 1996;11(6):1212. [CENTRAL: CN-00261230]
33. * Nordal KP, Halse J, Kronborg J, Dahl E, Hartmann A. Nasal calcitonin reduces bone loss in renal transplant recipients [abstract]. Journal of the American Society of Nephrology 1995;6(3):1109. [CENTRAL: CN-00485256]
34. Psimenou 2002 {published data only} * Psimenou E, Konstantinidou E, Giapraka N, Marinaki S, Kostakis A, Stathakis CP, et al.Randomized controlled study of calcitonin and etidronate in the treatment of osteoporosis in renal transplant patients [abstract]. XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (USA). 2002: CD-ROM.
35. Sharma 2002 {published data only} Sharma RK, Jeloka T, Gupta A, Gupta S, Gulati S, Kapoor R, et al.Effect of alendronate of post renal transplant osteoporosis: a randomised study [abstract]. Transplantation 2004;78(2 Suppl):60. [CENTRAL: CN-00509474]
36. Sharma RK, Jeloka T, Gupta A, Gupta S, Gulati S, Sharma AP, et al.Role of alendronate in post renal transplant osteoporosis: a randomised study [abstract]. Indian Journal of Nephrology 2002;12(4):236-7. [CENTRAL: CN-00461717]
37. Sharma RK, Jeloka T, Gupta S, Gupta S, Gulati S, Sharma AP, et al.Role of alendronate on post renal transplant osteoporosis: a randomised study [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):249. [CENTRAL: CN-00447697]
38. Talalaj 1996 {published data only} Talalaj M, Gradowska L, Marcinowska-Suchowierska E, Durlik M, Gaciong Z, Lao M. Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. Transplantation Proceedings 1996;28(6):3485-7. [MEDLINE: 8962355]
39. Torregrosa 2003 {published and unpublished data} Torregrosa JV, Moreno A, Gutierrez A, Vidal S, Oppenheimer F. Alendronate for treatment of renal transplant patients with osteoporosis. Transplantation Proceedings 2003;35(4):1393-5. [MEDLINE: 12826169]
40. Torres 2004 {published data only} * Torres A, Garcia S, Gomez A, Gonzalez A, Barrios Y, Concepcion MT, et al.Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney International 2004;65(2):705-12. [MEDLINE: 14717945]
41. Ugur 2000 {published data only} * Ugur A, Guvener N, Isiklar I, Karakayali H, Erdal R. Efficiency of preventive treatment for osteoporosis after renal transplantation. Transplantation Proceedings 2000;32(3):556-7. [MEDLINE: 10812111]
42. Wissing 2005 {published data only} Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 2005;79(1):108-15. [MEDLINE: 15714177]
43. Wissing M, Broeders N, Schoutens A, Abramowicz D. A prospective and randomized study of calcium and cholecalciferol treatment to prevent bone loss after renal transplantation [abstract]. Journal of the American Society of Nephrology 2001;12(Program & Abstracts):952A. [CENTRAL: CN-00550566]
44. Al Gabri 2005 {published data only} Al Gabri S, Zadrazil J, Krejci K, Horak P, Bachleda P. Changes in bone mineral density and selected metabolic parameters over 24 months following renal transplantation. Transplantation Proceeding 2005;37(2):1014-9. [MEDLINE: 15848609]
45. Aroldi 1997 {published data only} Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplantation 1997;63(3):380-6. [MEDLINE: 9039927]
46. Campistol 1999 {published data only} Campistol JM, Backman L, Brattstrom C, Kreis H, Morales JM, Sirolimus European Renal Transplant Study Group. Influence of immunosuppressive treatment on markers of bone remodeling in renal transplantation: comparison between cyclosporine and sirolimus [abstract]. Journal of the Amercian Society of Nephrology 1999;10(Program & Abstracts):754A. [CENTRAL: CN-00550450]
47. Campistol 2000 {published data only} Campistol JM, Cole E, Gioud-Paquet M, US European and Global Renal Transplant Study Groups. Sirolimus (rapamune): effects on bone in renal transplant patients [abstract]. Transplantation 2000; 69(8 Suppl):S289. [CENTRAL: CN-00444659]
48. El Haggan 2002 {published data only} El Haggan W, Barthe N, Vendrely B, Chauveau P, Berger F, Aparicio M, et al.One year evolution of bone mineral density in kidney transplant recipients receiving tacrolimus versus cyclosporine. Transplantation Proceedings 2002;34(5):1817-8. [MEDLINE: 12176589]
49. Falkiewicz 2005 {published data only} Falkiewicz K, Bidzinska B, Demissie M, Boratynska M, Zmonarski SC, Tworowska K, et al.Influence of vitamin D receptor gene polymorphisms on secondary hyperparathyroidism and bone density after kidney transplantation. Transplantation Proceedings 2005;37(2):1023-5. [MEDLINE: 15848611]
50. Hawley 1995 {published data only} * Hawley CM, McIntyre HD, Brown AM. Prospective study of bone mineral density and body composition following renal transplantation [abstract]. Journal of the American Society of Nephrology 1995;6(3):1124. [CENTRAL: CN-00484277]
51. James 2003 {published data only} James G, Raggi P, Boulay A, Burke S, Chasan-Taber S, Chertow G, et al.Thoracic vertebral bone density increases with renagel and decreases with calcium-based phosphate binder therapy - a two year study [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):681. [CENTRAL: CN-00445894]
52. Josephson 2000 {published data only} * Josephson MA, Schumm LP, Chiu MY, Marshall C, Sprague SM. Calcium and calcitriol prophylaxis against post-transplant bone loss [abstract]. Journal of the American Society of Nephrology 2000;11 (Program & Abstracts):720A.
53. Josephson 2004 {published data only} Josephson MA, Schumm LP, Chiu MY, Marshall C, Thistlethwaite JR, Sprague SM. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation 2004;78(8):1233-6. [MEDLINE: 15502727]
54. Kovac 2001 {published data only} * Kovac D, Lindic J, Kandus A, Bren AF. Bone mineral density in kidney transplant recipients. Transplantation Proceedings 2001;33 (7-8):3668-9. [MEDLINE: 11750560]
55. Kruse 2005 {published data only} Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrology Dialysis Transplantation 2005;20(7):1311-4. [MEDLINE: 15941846]
56. Labib 1999 {published data only} Labib B, Ibrahim MA, El Shawarby M, Abudl Rahman A, Abdel Wahab M, Elagroudy A. Effect of calculation therapy on renal osteodystrophy [abstract]. XXXVI Congress of the European Renal Association European Dialysis & Transplant Association; 1999 Sep 5-8; Madrid (Spain). 1999:42.
57. Lippuner 1996 {published data only} Lippuner K, Haller B, Casez JP, Montandon A, Jaeger P. Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticosteroids: a prospective, randomized, double-blind study. Mineral & Electrolyte Metabolism 1996;22(4):207-13. [MEDLINE: 8807623]
58. Lippuner 1998 {published data only} Lippuner K, Casez JP, Horber F, Dijkhuis E, Jaeger P. Glucocorticosteroids (GC) early after kidney transplantation (KT): beneficial effect of deflazacort (DFZ) versus prednisone (PRED) on bone and body composition in a double blind study [abstract]. Journal of the Amercian Society of Nephrology 1997;8(Program & Abstracts):692A. [CENTRAL: CN-00446424]
59. Lippuner K, Casez JP, Horber FF, Jaeger P. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. Journal of Clinical Endocrinology & Metabolism 1998;83(11):3795-802. [MEDLINE: 9814449]
60. Masse 2001 {published data only} * Masse M, Girardin C, Ouimet D, Dandavino R, Boucher A, Madore F, et al.Initial bone loss in kidney transplant recipients: a prospective study. Transplantation Proceedings 2001;33(1-2):1211. [MEDLINE: 11267262]
61. Nowacka-Cieciura 01 {published data only} Nowacka-Cieciura E, Durlik M, Cieciura T, Talalaj M, Kukula K, Lewadowska D, et al.Positive effect of steroid withdrawal on bone mineral density in renal allograft recipients [abstract]. XVIII International Congress of the Transplantation Society; 2000 Aug 27 Sept 1; Rome (Italy). 2000.
62. Nowacka-Cieciura E, Durlik M, Cieciura T, Talalaj M, KukuLa K, Lewandowska D, et al.Positive effect of steroid withdrawal on bone mineral density in renal allograft recipients. Transplantation Proceedings 2001;33(1-2):1273-7. [MEDLINE: 11267289]
63. Pieper 2004 {published data only} Pieper AK, Buhle F, Bauer S, Mai I, Budde K, Haffner D, et al.The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrology Dialysis Transplantation 2004;19(10): 2630-3. [MEDLINE: 15304561]
64. Raggi 2004 {published data only} * Raggi P, Burke S, Chasen-Taber S, Chertow G, Holzer H, Bommer J. Sevelamer preserves trabecular bone mineral density [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon (Portugal). 2004:103-4. [CENTRAL: CN-00509430]
65. Reed 2004 {published data only} Reed J, Keightley G, Blumenthal S, Bradley C, LaBrecque J, Turner S, et al.The CONTROL STUDY: enhanced achievement of NKFK/DOQITM bone metabolism and disease targets using cinacalcet HCI (SensiparTM) [abstract no: F-PO986]. Journal of the Amercian Society of Nephrology 2004;15(Program & Abstracts): 280A-281A. [CENTRAL: CN-00550527]
66. Rigotti 2003 {published data only} Rigotti P, Vialtel P, Pascual J, Sanchez-Fructuoso A, Escuin F, the Bone Mineral Density Study Group. Immunosuppression without maintenance steroids prevents decline of bone mineral density following renal transplantation [abstract]. American Journal of Transplantation 2003;3(Suppl 5):199. [CENTRAL: CN-00447406]
67. Serra 2005 {published data only} Serra AL, Schwarz AA, Wick FH, Marti HP, Wuthrich RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrology Dialysis Transplantation 2005;20(7):1315-9. [MEDLINE: 15941845]
68. Sezer 2005 {published data only} Sezer S, Uyar M, Arat Z, Ozdemir FN, Haberal M. Potential effects of 1,25-dihydroxyvitamin D3 in renal transplant recipients. Transplantation Proceedings 2005;37(7): 3109-11. [MEDLINE: 16213322]
69. ter Meulen 2004 {published data only} ter Meulen CG, van Riemsdijk I, Hene RJ, Christiaans MH, Borm GF, Corstens FH, et al.No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study. Transplantation 2004;78(1):101-6. [MEDLINE: 15257046]
70. ter Meulen CG, van Riemsdijk IC, Hene RJ, Christiaans MHL, van Gelder T, Hilbrands LB, et al.A prospective randomized trial comparing steroid-free immunosuppression with limited steroid exposure on bone mineral density in the first year after renal transplantation [abstract no:0344]. XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (USA). 2002.
71. Toro 2005 {published data only} Toro J, Gentil MA, Garcia R, Perez-Valdivia MA, Garcia AE, Algarra GR, et al.Alendronate in kidney transplant patients: a single-center experience. Transplantation Proceedings 2005;37(3): 1471-2. [MEDLINE: 15866643]
72. Torregrosa 1995 {published data only} * Torregrosa JV, Campistol JM, Montesinos M, Fenollosa B, Pons F, Martinez de Osaba MJ, et al.Factors involved in the loss of bone mineral density after renal transplantation. Transplantation Proceedings 1995;27(4):2224-5. [MEDLINE: 7652782]
73. van den Ham 2000 {published data only} van den Ham EC, Christiaans MH, Heidendal GA, van-Hooff JP. Effects of different steroid dosages on bone mineral density and body composition in renal transplant patients [abstract]. Clinical Nutrition 1998;17(Suppl 1):44. [CENTRAL: CN-00285279]
74. van den Ham ECH, Kooman JP, Christiaans MHL, van Hooff JP. The influence of early steroid withdrawal on bone mineral density in renal transplant patients [abstract]. Journal of the American Society of Nephrology 2000;11(Program & Abstracts):711A. [CENTRAL: CN-00550714]
75. Vasquez 2004 {published data only} Vasquez EM, Sifontis N, Jacobssen V, Testa G, Sankary H, Benedetti E. Simvastatin for prevention of bone loss following renal transplantation. [abstract]. Transplantation 2004;78(2 Suppl):293. [CENTRAL: CN-00509537]
76. Zaoui 2003 {published data only} Zaoui P, Vialtel P, Rigotti P, Pascual J, Sanchez-Fructuoso A, Escuin F, the Bone Mineral Density Study Group. A steroid-free immunosuppressive regimen of Daclizumab, Tacrolimus and MMF prevents loss of bone mass following renal transplantation [abstract]. Nephrology Dialysis Transplantation 2003;18(Suppl 4):495. [CENTRAL: CN-00448519]
77. NCT00266708 {published data only} Coco M, Glicklich D. Randomised trial of risedronate to prevent bone loss in renal transplant recipients. http://www.clinicaltrials.gov/ct/show/NCT00266708.
78. Abbott 2001 Abbott KC, Oglesby RJ, Hypolite IO, Kirk AD, Ko CW, Welch PG, et al.Hospitalizations for fractures after renal transplantation in the United States. Annals of Epidemiology 2001;11(7):450-7. [MEDLINE: 11557176]
79. Adachi 1997 Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al.Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. New England Journal of Medicine 1997;337(6):382-7. [MEDLINE: 9241127]
80. Almond 1994 Almond MK, Kwan JT, Evans K, Cunningham J. Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron 1994;66(1):52-7. [MEDLINE: 8107953]
81. Chambers 1980 Chambers TJ. Diphosphonates inhibit bone resorption by macrophages in vitro. Journal of Pathology 1980;132(3):255-62. [MEDLINE: 7431161]
82. Chesnut 2000 Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al.A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. American Journal of Medicine 2000;109(4):267-76. [MEDLINE: 10996576]
83. Cunningham 2004 Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, et al.Osteoporosis in chronic kidney disease. American Journal of Kidney Diseases 2004;43(3):566-71. [MEDLINE: 14981616]
84. De Nijs 2004 de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporosis International 2004;15(8):589-602. [MEDLINE: 15138667]
85. de Vries 1982 de Vries E, van der Weij JP, van der Veen CJ, van Paassen HC, Jager MJ, Sleeboom HP, et al.In vitro effect of (3-amino-1- hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation. Immunology 1982;47(1):157- 63. [MEDLINE: 6214497]
86. Dickersin 1994 Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286- 91. [MEDLINE: 7718048]
87. Durieux 2002 Durieux S, Mercadal L, Orcel, P, Dao H, Rioux C, Bernard M, et al.Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation 2002;74(4):438-9. [MEDLINE: 12352908]
88. Fryer 1996 Fryer J, Grant D, Jiang J, Metrakos P, Ozcay N, Ford C, et al.Influence of macrophage depletion on bacterial translocation and rejection in small bowel transplantation. Transplantation 1996;62 (5):553-8. [MEDLINE: 8830814]
89. Grey 1994 Grey AB, Cundy TF, Reid IR. Continuous combined oestrogen/ progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clinical Endocrinology 1994;40(5):671-7. [MEDLINE: 8013147]
90. Grotz 1994 Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 1994;58(8):912-5. [MEDLINE: 7940734]
91. Grotz 1995 Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski M, Exner VM, et al.Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients. Nephrology Dialysis Transplantation 1995;10(11):2096-100. [MEDLINE: 8643174]
92. Hahn 1981 Hahn TJ, Halstead LR, Baran DT. Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. Journal of Clinical Endocrinology & Metabolism 1981;52(1):111-5. [:EMBASE: 1981058063]
93. Hariharan 2001 Hariharan S. Long-term kidney transplant survival. American Journal of Kidney Diseases 2001;38(6 Suppl 6):S44-50. [MEDLINE: 11729005]
94. Heaf 2000 Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Clinical Transplantation 2000;14(5):457-63. [MEDLINE: 11048990]
95. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557- 60. [MEDLINE: 12958120]
96. Horber 1994 Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger P. Changes in bone mass early after kidney transplantation. Journal of Bone & Mineral Research 1994;9(1):1-9. [MEDLINE: 8154303]
97. Hung 1996 Hung CJ, Lee PC, Song CM, Chang YT, Tsai MT, Dai YS, et al.Clinical implication of hormone treatment in postmenopausal kidney transplants. Transplantation Proceedings 1996;28(3):1548-50. [MEDLINE: 8658780]
98. Jeffrey 2003 Jeffrey JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation 2003;76(10):1498-502. [MEDLINE: 14657693]
99. Julian 1991 Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. New England Journal of Medicine 1991;325(8):544- 50. [MEDLINE: 1857390]
100. Karachalios 2004 Karachalios T, Lyritis GP, Kaloudis J, Roidis N, Katsiri M. The effects of calcitonin on acute bone loss after pertrochanteric fractures. Journal of Bone & Joint Surgery - British Volume 2004;86(3):350-8. [MEDLINE: 15125121]
101. Lefebvre 1996 Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia). 1996.
102. Master List 2007 United States Cochrane Center. Master list of journals being searched. http://apps1.jhsph.edu/cochrane/masterlist.asp (accessed May 2007).
103. Monier-Faugere 2000 Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. Journal of the American Society of Nephrology 2000;11(6):1093-9. [MEDLINE: 10820173]
104. Nisbeth 1999 Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellstrom B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 1999;67(9):1218-22. [MEDLINE: 10342312]
105. O'Shaunessy 2002 O'Shaughnessy EA, Dahl DC, Smith CL, Kasiske BL. Risk factors for fractures in kidney transplantation. Transplantation 2002;74(3): 362-6. [MEDLINE: 12177615]
106. Pichette 1996 Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. American Journal of Kidney Diseases 1996;28(1):105-14. [MEDLINE: 8712204]
107. Reid 1996 Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Archives of Internal Medicine 1996;156(11):1173-7. [MEDLINE: 8639011]
108. Sambrook 1988 Sambrook PN, Eisman JA, Champion GD, Pocock NA. Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis & Rheumatism 1988;31(8):973-8. [MEDLINE: 2970263]
109. Sprague 2004 Sprague SM, Josephson MA. Bone disease after kidney transplantation. Seminars in Nephrology 2004;24(1):82-90. [MEDLINE: 14730514]
110. Torres 2002 Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. Journal of the American Society of Nephrology 2002;13(2):551-8. [MEDLINE: 11805187]
111. Vautour 2004 Vautour LM, Melton LJ 3rd, Clarke BL, Achenbach SJ, Oberg AL, McCarthy JT. Long-term fracture risk following renal transplantation: a population based study. Osteoporosis International 2004;15(2): 160-7. [MEDLINE: 14666400]
112. Veenstra 1999 Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. American Journal of Kidney Diseases 1999;33 (5):829-39. [MEDLINE: 10213637]
113. Palmer 2004 Palmer SC, McGregor DO, Strippoli GFM. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858. CD005015]
114. Palmer 2005a Palmer SC, McGregor DO, Strippoli GFM. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858. CD005015.pub2]
115. Palmer 2005b Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. American Journal of Kidney Diseases 2005;45(4):638-49. [MEDLINE: 15806466]